Bioadaptives (BDPT) Cost of Revenue (2016 - 2026)

Bioadaptives has disclosed Cost of Revenue across 9 years of filings, most recently posting $1401.0 for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1401.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $7182.0 (up 2819.51% YoY), and the FY2025 annual result was $5781.0, down 33.08% from the prior year.
• Cost of Revenue came in at $1401.0 for Q1 2026 at Bioadaptives, down from $2844.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $10999.0 in Q3 2023 to a low of $246.0 in Q2 2024.
• The 5-year median for Cost of Revenue is $2162.5 (2022), against an average of $3115.5.
• Across the five-year window, Cost of Revenue sank 71.02% in 2024 and jumped 776.42% in 2025, its largest moves.
• Bioadaptives' Cost of Revenue stood at $2954.0 in 2022, then surged by 52.4% to $4502.0 in 2023, then plunged by 94.54% to $246.0 in 2024, then surged by 1056.1% to $2844.0 in 2025, then sank by 50.74% to $1401.0 in 2026.
• The last three Cost of Revenue figures came in at $1401.0 (Q1 2026), $2844.0 (Q4 2025), and $781.0 (Q3 2025), per Business Quant data.